MedMira Receives Canadian Patent for Innovative Diagnostic System

HALIFAX, NS / ACCESSWIRE / March 13, 2024 - MedMira Inc. (TSXV:MIR) has secured a Canadian patent (number 2,949,634) for its new quantitative test system, enhancing its diagnostic test portfolio. This follows the U.S. patent (number 11,353,450) awarded in 2022. The company's Rapid Vertical Flow Technology® (RVF) underpins these advances, aiming to streamline the diagnostics process from initial screening to monitoring disease progression efficiently.

CEO Hermes Chan emphasized the integration of MedMira's RVF and MIROQ™ technologies, delivering rapid, high-quality, qualitative, and quantitative diagnostic results. This innovation aims to optimize Point-of-Care testing, facilitating immediate patient treatment. The synergy of these technologies ensures high-quality results within minutes, aiming to replace the slower, more costly conventional methods.

The novel diagnostic system combines RVF with Surface-Enhanced Raman Spectroscopy (SERS) to amplify test sensitivity and reproducibility. MedMira's approach enhances the capacity for multiplexed diagnostics, promising qualitative and quantitative results promptly. This development marks a significant stride in making advanced diagnostics accessible and efficient, streamlining patient care.